The Danish biotechnology company Novonesis has had a strong start to 2025. In the first nine months of the year, organic sales grew by 8 per cent, and the company is now raising its full-year guidance from 6–8 per cent to 7–8 per cent.

In a press release on 6 November, President and CEO Ester Baiget highlighted the solid results:

• I am pleased with our performance in the first nine months, during which we delivered 8% organic sales growth with solid profitability. Our results were strong across all sales regions – both in growth markets and developed markets. We delivered an adjusted EBITDA margin of 37.3% despite significant currency headwinds, which demonstrates the strength and resilience of our business model.

Growth was broadly based across the business areas. Food & Health grew organically by 9 per cent, while Planetary Health increased by 8 per cent. Geographically, the strongest progress was seen in the growth markets, which grew by 12 per cent, while sales in the mature markets rose by 6 per cent.

The adjusted EBITDA margin came in at 37.3 per cent, and adjusted net profit increased by 22 per cent. Novonesis reported a debt level of 2.0 times EBITDA and a free cash flow before acquisitions of EUR 668 million.

According to the company, the development reflects continued execution on its strategic priorities, which will help Novonesis deliver on its 2030 ambitions.

Read the full press release HERE

Photo: Novonesis

by LWM